Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________ FORM 10-Q ________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________________ to ________________ Commission File N ...

Rapid Micro Biosystems, Inc. (NASDAQ:RPID) Q2 2022 Earnings Conference Call August 12, 2022 8:30 AM ET Company Participants Mike Beaulieu - CFA Vice President, Investor Relations & Corporate Communications Rob Spignesi - Chief Executive Officer Sean Wirtjes - Chief Financial Officer Conference Call Participants Yuko Oku - Morgan Stanley Dan Arias - Stifel Stephanie Yan - Cowen Rachel Cascio - JPMorgan Operator Ladies and gentlemen, thank you for standing by and welcome to the Rapid Micro Biosystems Second Q ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40592 Rapid Micro Biosystems, Inc. (Exact name of registrant as specified in its charter) Delaware 20-8121647 ...

Financial Data and Key Metrics Changes - The company reported Q1 2022 revenue of $4.2 million, down from $4.8 million in Q1 2021, primarily due to fewer placements of Growth Direct Systems [21] - Product revenue, which includes Systems and Consumables, was $2.6 million in Q1 2022 compared to $3.7 million in the same quarter last year [21] - Net loss for Q1 2022 was $14.9 million, an improvement from a net loss of $22.1 million in Q1 2021, which included an $11.4 million charge related to preferred stock warrants [31] Business Line Data and Key Metrics Changes - Recurring revenue grew 66% to $2.7 million in Q1 2022, driven by strong growth in both Consumables and Service Contracts [26] - Consumables revenue increased nearly 100% year-over-year, benefiting from a growing base of validated systems and increased utilization [23] - Service revenue rose to $1.6 million in Q1 2022 from $1.1 million in Q1 2021, driven by a higher volume of validations [25] Market Data and Key Metrics Changes - The cumulative number of validated systems in the field grew from 52 to 93, an increase of 79% over the past four quarters [23] - Consumables revenue per average validated system increased 15%, with some individual customer systems achieving annual run rates over $200,000 [23] Company Strategy and Development Direction - The company is focused on improving system placements enterprise-wide and has strengthened its commercial team to drive growth [16][20] - New product development is a priority, with upcoming launches in rapid sterility and mold detection products expected to resonate strongly with customers [18][20] - The company aims to enhance its global commercial capability, viewing it as critical to its growth strategy [16] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about improving customer site access, which is crucial for system sales [41] - The company anticipates that system placements will accelerate in the second half of the year, with expectations for 85% of placements occurring in that period [35] - Management remains confident in the long-term growth potential, citing a large total addressable market and a strong value proposition [20] Other Important Information - The company is actively managing inflationary pressures and does not expect material business impacts from these challenges [29] - Total operating expenses increased to $13.1 million in Q1 2022, up from $7.6 million in Q1 2021, primarily due to investments in commercial and product development [30] Q&A Session Summary Question: Placement expectations for the first and second half of the year - Management confirmed that the math regarding placements is correct, with expectations for a significant increase in the second half of the year [40][41] Question: Ability to increase prices amid inflation - Management indicated plans to implement price hikes across many products, with some benefits already being observed [45] Question: Customer mix and end market applications - The majority of the customer base consists of larger enterprises, but there is also engagement with smaller and mid-sized companies [48][50] Question: Confidence in the cell and gene therapy market - Management remains optimistic about the cell and gene therapy market, noting a healthy pipeline and strong customer engagement [53][54] Question: Competitive landscape - Management views the competitive intensity as low, with the primary competition being traditional manual methods [55]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40592 Rapid Micro Biosystems, Inc. (Exact name of registrant as specified in its charter) Delaware 20-8121647 ...

TABLE OF CONTENTS | | | Page | | --- | --- | --- | | PART I | | | | Item 1. | Business | 7 | | Item 1A.Risk Factors | | 37 | | Item 1B. Unresolved Staff Comments | | 76 | | Item 2. | Properties | 76 | | Item 3. | Legal Proceedings | 76 | | Item 4. | Mine Safety Disclosures | 76 | | PART II | | | | Item 5. | Market for Registrant's Common Equity, Related Stockholder Matters and Issuer | | | Purchases of Equity Securities | | 78 | | Item 6. | Reserved | 78 | | Management's Discussion and Analysis of Financial ...

Rapid Micro Biosystems MARCH 2022 This presentation has been prepared by Rapid Micro Biosystems, Inc. (the "Company") solely for informational purposes. This presentation contains forward-looking statements. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements relating to the our full year 2022 commercial revenue outlook range and expected future revenue and growth; accelerati ...

Rapid Micro Biosystems MARCH 2022 This presentation has been prepared by Rapid Micro Biosystems, Inc. (the "Company") solely for informational purposes. This presentation contains forward-looking statements. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements relating to the our full year 2022 commercial revenue outlook range and expected future revenue and growth; accelerati ...

Rapid Micro Biosystems Inc. (NASDAQ:RPID) Q4 2021 Earnings Conference Call March 4, 2022 8:30 AM ET Company Participants Mike Beaulieu - CFA Vice President, Investor Relations and Corporate Communications Rob Spignesi - President and Chief Executive Officer Sean Wirtjes - Chief Financial Officer Conference Call Participants Max Masucci - Cowen Casey Woodring - JPMorgan Dan Arias - Stifel Tejas Savant - Morgan Stanley Disclaimer*: This transcript is designed to be used alongside the freely available audio re ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40592 Rapid Micro Biosystems, Inc. (Exact name of registrant as specified in its charter) Delaware 20-812 ...